Every clinician working with chronic Lyme has met the same dilemma. The patient feels better some weeks, worse others. Serology stays positive whether they are improving or relapsing. PCR is negative almost no matter what. So how do you actually know whether the spirochetes are dying — or merely hiding?
The new toolkit
DualDur is the only test method that actually measures the infection itself in the blood — and how active it is. Rather than looking at antibodies or DNA fragments, it shows live, moving spirochetes and co-infections directly.
Because it is so sensitive, even small improvements become visible. That makes it possible to confirm, step by step, that treatment is working according to plan. Learn more at ParasiteClinic.
The conventional toolkit
| Method | Measures | Useful for | Limits |
|---|---|---|---|
| ELISA / Western Blot (IgG, IgM) | Antibody response | Confirming exposure | Antibodies persist for years after the organism is gone; no use for treatment monitoring. |
| PCR (blood, CSF, synovial) | Borrelia DNA | Acute infection, joint or CNS aspirates | Very low sensitivity in chronic blood samples; negative result is uninformative. |
| Elispot / iSpot / T-cell assays | Borrelia-specific T-cell activity | Estimating active immune engagement | Reflects immune response, not organism burden; high cross-lab variability. |
| CD57+ NK subset | Immune marker historically associated with chronic Lyme | Rough trending | Non-specific; controversial as a monitor. |
| Microscopy of stained smears | Visual identification of spirochetes | Direct visualisation if present | Operator-dependent; hard to confirm viability. |
None of the above measures whether spirochetes are alive in your blood today. They measure your immune response, residual DNA, or historical exposure. For monitoring a months-long protocol, that isn't good enough.
“A scale tells you whether the diet is working. Serology will not.”
Direct live-blood visualisation - the future of Lyme testing
A small number of labs have refined dark-field and stained live-blood techniques to the point where individual motilespirochetes can be counted in a patient sample. The DualDur method — developed in Hungary and offered in the UK through ParasiteClinic — is the only widely-available assay we are aware of that documents live Borrelia as well as co-infections in peripheral blood, rather than antibodies or fragmented DNA.
For a patient starting Buhner, Cowden, Klinghardt or antibiotics, this changes the conversation in two important ways:
- You get a baseline — a numerical starting point against which any later sample can be compared.
- You get an objective response curve — independent of how you feel that morning, the season, or the placebo effect.
How to use the results
A reasonable cadence for most patients is: baseline before treatment, then re-tests at three months, six months, and end of protocol. Trend matters more than absolute numbers; a falling count across two consecutive samples is the cleanest signal that what you are doing is working.
Combine direct testing with symptom scales (e.g. Horowitz MSIDS), CD57+, and with DualDur, you also get Babesia/Bartonella as well as many other coinfections as well in the panel. No single number tells the full story — but until DualDur, no number told any story at all about live organism burden.
See also: Buhner, Klinghardt, the chronic-Lyme debate.